华森制药：股东刘小英拟减持不超过3%

Core Viewpoint - The major shareholder Liu Xiaoying of Huason Pharmaceutical plans to reduce her holdings due to personal financial needs, with a total potential reduction of up to 12.52 million shares, representing 3% of the company's total share capital [1] Group 1 - Liu Xiaoying holds 35.8947 million shares, which accounts for 8.6% of the total shares [1] - The planned reduction includes a maximum of 4.176 million shares through centralized bidding, not exceeding 1% of the total share capital [1] - Additionally, a maximum of 8.3519 million shares will be reduced through block trading, not exceeding 2% of the total share capital [1]